Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Hurwitz · SciRah

Researcher profile · Semantic Scholar

H. Hurwitz

Share profile

H. Hurwitz — researcher profile on SciRah

h-index: 76
Works: 408
Citations: 34K

Most-cited papers

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, H. Hurwitz, A. Sandler, D. Miles +3 more
2020Cancer Treatment Reviews975 citations Open access
Semantic Scholar
Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study
F. Meric-Bernstam, H. Hurwitz, K. Raghav, R. McWilliams +14 more
2019The Lancet Oncology443 citations Open access
Semantic Scholar
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
J. Hainsworth, F. Meric-Bernstam, C. Swanton, H. Hurwitz +8 more
2018Journal of Clinical Oncology418 citations Open access
Semantic Scholar
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S. Siena, A. Sartore-Bianchi, S. Marsoni, H. Hurwitz +5 more
2018Annals of Oncology221 citations Open access
Semantic Scholar
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
C. Cremolini, C. Antoniotti, A. Stein, J. Bendell +8 more
2020Journal of Clinical Oncology189 citations Open access
Semantic Scholar
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen, H. Hurwitz
2018Cancer Journal183 citations
Semantic Scholar
Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
J. Tabernero, I. Melero, W. Ros, G. Argilés +16 more
2017144 citations
Semantic Scholar
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
L. Renfro, F. Loupakis, R. Adams, M. Seymour +20 more
2016Journal of Clinical Oncology131 citations Open access
Semantic Scholar
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
N. Mettu, F. Ou, T. Zemla, T. Halfdanarson +12 more
2022JAMA Network Open111 citations Open access
Semantic Scholar
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
H. Hurwitz, E. Van Cutsem, J. Bendell, M. Hidalgo +12 more
2018Investigational new drugs108 citations Open access
Semantic Scholar
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
K. Sjoquist, L. Renfro, R. Simes, Niall C. Tebbutt +29 more
2018Journal of the National Cancer Institute103 citations Open access
Semantic Scholar
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
H. Hurwitz, B. Tan, J. Reeves, H. Xiong +10 more
2019The Oncologist72 citations Open access
Semantic Scholar
BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
N. Mettu, E. Twohy, F. Ou, T. Halfdanarson +15 more
2019Annals of Oncology66 citations Open access
Semantic Scholar
Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
M. Javle, J. Hainsworth, C. Swanton, H. Burris +10 more
201758 citations
Semantic Scholar
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
J. Bendell, T. Saurí, A. C. Gracián, R. Álvarez +22 more
2019The Oncologist44 citations Open access
Semantic Scholar
Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218
A. A. Secord, Kirsten Bell Burdett, K. Owzar, D. Tritchler +17 more
2020Clinical Cancer Research39 citations Open access
Semantic Scholar
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
E. Chan, E. Chiorean, P. O'Dwyer, N. Gabrail +4 more
2018Cancer Chemotherapy and Pharmacology39 citations
Semantic Scholar
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
L. Renfro, R. Goldberg, A. Grothey, A. Sobrero +23 more
2017Journal of Clinical Oncology39 citations Open access
Semantic Scholar
Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.
H. Hurwitz, K. Raghav, H. Burris, R. Kurzrock +12 more
201739 citations
Semantic Scholar
Development of a Novel c-MET–Based CTC Detection Platform
Tian Zhang, R. Boominathan, Brad Foulk, C. Rao +16 more
2016Molecular Cancer Research39 citations Open access
Semantic Scholar
Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma
J. Wallin, M. Pishvaian, Genevive Hernandez, Mahesh Yadav +15 more
201634 citations
Semantic Scholar
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.
H. Hurwitz, J. Hainsworth, C. Swanton, E. Perez +9 more
201631 citations
Semantic Scholar
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
R. García-Carbonero, E. Van Cutsem, F. Rivera, J. Jassem +16 more
2017The Oncologist30 citations Open access
Semantic Scholar
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
J. Berlin, R. Ramanathan, J. Strickler, Deepa S. Subramaniam +11 more
2018British Journal of Cancer27 citations Open access
Semantic Scholar
A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies.
David C. Smith, C. Britten, D. Clary, L. Nguyen +2 more
2016Journal of Clinical Oncology27 citations
Semantic Scholar
Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Xiaoju Max Ma, J. Bendell, H. Hurwitz, Christine Ju +10 more
2020Clinical Cancer Research26 citations Open access
Semantic Scholar
Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
V. Keedy, T. Bauer, J. Clarke, H. Hurwitz +8 more
201826 citations
Semantic Scholar
LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).
G. Argilés, J. Saro, N. Segal, I. Melero +22 more
2017Annals of Oncology25 citations Open access
Semantic Scholar
Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).
H. Hurwitz, E. Van Cutsem, J. Bendell, M. Hidalgo +12 more
201724 citations
Semantic Scholar
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
G. Vlahović, K. Meadows, A. Hatch, J. Jia +15 more
2018The Oncologist21 citations Open access
Semantic Scholar
Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer
J. Seligmann, A. Hatch, S. Richman, F. Elliott +7 more
2017JAMA Oncology21 citations Open access
Semantic Scholar
Genetic Variants in the Platelet-Derived Growth Factor Subunit B Gene Associated with Pancreatic Cancer Risk
B. Duan, Jiangfeng Hu, Hong-Liang Liu, Yanru Wang +8 more
2017International Journal of Cancer21 citations Open access
Semantic Scholar
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors
C. Kollmannsberger, H. Hurwitz, L. Bazhenova, B. Cho +11 more
2022Targeted oncology20 citations Open access
Semantic Scholar
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer
A. Grothey, J. Strosberg, L. Renfro, H. Hurwitz +11 more
2017Clinical Cancer Research20 citations
Semantic Scholar
Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.
A. Bryce, R. Kurzrock, F. Meric-Bernstam, H. Hurwitz +10 more
201720 citations
Semantic Scholar
403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)
N. Segal, J. Saro, I. Melero, W. Ros +16 more
201719 citations Open access
Semantic Scholar
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
A. Hatch, Alexander B. Sibley, Mark D. Starr, J. Brady +10 more
2016Cancer Medicine19 citations Open access
Semantic Scholar
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
J. Strickler, Christel N. Rushing, H. Uronis, M. Morse +16 more
2021The Oncologist17 citations Open access
Semantic Scholar
Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance)
A. Nixon, Alexander B. Sibley, Ying-Miao Liu, A. Hatch +14 more
2021Clinical Cancer Research17 citations Open access
Semantic Scholar
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
F. Loupakis, H. Hurwitz, L. Saltz, D. Arnold +6 more
2018British Journal of Cancer17 citations Open access
Semantic Scholar
Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.
J. Ronald, A. Nixon, D. Marin, Rajan T. Gupta +9 more
2017Radiology17 citations
Semantic Scholar
Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
J. Bendell, B. Tan, J. Reeves, H. Xiong +7 more
201617 citations
Semantic Scholar
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Ying-Miao Liu, Mark D. Starr, J. Brady, Christel N. Rushing +6 more
2018Molecular Cancer Therapeutics16 citations Open access
Semantic Scholar
Genetic variation determines VEGF-A plasma levels in cancer patients
F. Innocenti, Chen Jiang, Alexander B. Sibley, A. Etheridge +16 more
2018Scientific Reports14 citations Open access
Semantic Scholar
Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.
J. Hainsworth, F. Meric-Bernstam, C. Swanton, H. Hurwitz +10 more
201614 citations
Semantic Scholar
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
R. Cohen, M. Raeisi, Q. Shi, B. Chibaudel +16 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study
F. Meric-Bernstam, H. Hurwitz, R. Singh, R. McWilliams +14 more
201913 citations
Semantic Scholar
Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).
A. Nixon, Alexander B. Sibley, A. Hatch, Ying-Miao Liu +12 more
201613 citations
Semantic Scholar
Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).
M. Morse, D. Halperin, H. Uronis, David S. Hsu +8 more
2021Journal of Clinical Oncology12 citations
Semantic Scholar
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.
C. Cremolini, C. Antoniotti, A. Stein, J. Bendell +7 more
2020Journal of Clinical Oncology12 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Nixon×10
Invite
A. Nixon — researcher profile on SciRah
J. Bendell×9
Invite
J. Bendell — researcher profile on SciRah
F. Meric-Bernstam×8
Invite
F. Meric-Bernstam — researcher profile on SciRah
C. Swanton×8
Invite
C. Swanton — researcher profile on SciRah

×8

Invite

H. Burris — researcher profile on SciRah

Invite

R. Bose — researcher profile on SciRah

Invite

D. Spigel — researcher profile on SciRah

Invite

M. Beattie — researcher profile on SciRah

J. Hainsworth×8

Invite

J. Hainsworth — researcher profile on SciRah

Invite

H. Lenz — researcher profile on SciRah

D. Niedzwiecki×8

Invite

D. Niedzwiecki — researcher profile on SciRah

Invite

R. Kurzrock — researcher profile on SciRah